Psilocybin changes the brain at the cellular level — now shown in human neurons for the first time
Until recently, the evidence for psilocybin's restorative effects came almost exclusively from animal studies. Now researchers have exposed the active compound, psilocin, to human brain cells in a petri dish for the first time — and what they found differs in important ways from what mice had suggested.
Psilocybin is being investigated as a treatment for treatment-resistant depression, anxiety disorders and addiction. In the body, it is rapidly converted into psilocin, which binds to the 5-HT2A serotonin receptor. Animal studies had already shown that this strengthens synaptic connections and stimulates protein synthesis — processes tied to neuroplasticity, the brain's ability to forge new connections. But whether the same thing happens in human neurons was, until now, unknown.
For this study, the researchers used what are known as iPSC-derived neurons: brain cells grown from induced pluripotent stem cells, which are themselves produced from ordinary human body cells. That technology makes it possible to study human brain tissue outside the body, without the need for brain biopsies. The cortical neurons were exposed to psilocin, and the researchers then mapped the molecular and cellular effects in detail.
Neuroplasticity: real change or measurement artifact?
The results confirm that psilocin promotes neuroplasticity in human neurons too — but the details diverge from what animal models had predicted. That is not a minor point: those very divergences determine whether findings from animal experiments can actually be translated into human treatments. Which specific signaling pathways are activated, how long the effects last, and whether the changes at the cellular level genuinely lead to the clinical improvements that patients report — these are questions this research raises but does not fully answer.
What this means for clinical practice
Psilocybin is currently in multiple clinical trials around the world. The European Union, the United Kingdom and the United States are all actively considering what regulation and potential approval might look like. Its effectiveness against depression appears real, yet the underlying mechanism is still only partially understood. That is precisely why this kind of mechanistic research matters: if you do not know how something works, you cannot optimize it or scale it safely. iPSC technology opens the door to personalized pharmacology — growing neurons from a specific patient and testing how they respond to a given compound. Whether that will ever become routine in psychiatry remains a distant prospect.